Free Trial
NASDAQ:ACTU

Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Actuate Therapeutics logo
$7.66 -0.02 (-0.26%)
Closing price 04:00 PM Eastern
Extended Trading
$7.66 +0.00 (+0.07%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Actuate Therapeutics Stock (NASDAQ:ACTU)

Key Stats

Today's Range
$7.46
$7.67
50-Day Range
$5.66
$8.67
52-Week Range
$5.47
$11.99
Volume
16,866 shs
Average Volume
69,857 shs
Market Capitalization
$158.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50
Consensus Rating
Buy

Company Overview

Receive ACTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACTU Stock News Headlines

Equities Analysts Offer Predictions for ACTU Q3 Earnings
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Headlines

ACTU Stock Analysis - Frequently Asked Questions

Actuate Therapeutics' stock was trading at $7.96 at the beginning of the year. Since then, ACTU shares have decreased by 3.8% and is now trading at $7.66.

Actuate Therapeutics, Inc. (NASDAQ:ACTU) issued its earnings results on Thursday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.11.

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering (IPO) on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Actuate Therapeutics' top institutional investors include BIOS Capital Management LP (48.68%), Voss Capital LP (1.40%), Geode Capital Management LLC (0.58%) and Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher.
View institutional ownership trends
.

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
8/14/2025
Today
8/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACTU
Previous Symbol
NASDAQ:ACTU
CIK
1652935
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$20.00
Potential Upside/Downside
+167.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.28 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-19,736.59%
Return on Assets
-281.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.73
Quick Ratio
0.46

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.13) per share
Price / Book
-58.92

Miscellaneous

Outstanding Shares
20,750,000
Free Float
6,360,000
Market Cap
$158.95 million
Optionable
N/A
Beta
N/A

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ACTU) was last updated on 8/21/2025 by MarketBeat.com Staff
From Our Partners